Dataset Information


A Novel l-Asparaginase with low l-Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias In Vivo.

ABSTRACT: Acute lymphoblastic leukemia (ALL) is the most common type of pediatric cancer, although about 4 of every 10 cases occur in adults. The enzyme drug l-asparaginase serves as a cornerstone of ALL therapy and exploits the asparagine dependency of ALL cells. In addition to hydrolyzing the amino acid l-asparagine, all FDA-approved l-asparaginases also have significant l-glutaminase coactivity. Since several reports suggest that l-glutamine depletion correlates with many of the side effects of these drugs, enzyme variants with reduced l-glutaminase coactivity might be clinically beneficial if their antileukemic activity would be preserved. Here we show that novel low l-glutaminase variants developed on the backbone of the FDA-approved Erwinia chrysanthemi l-asparaginase were highly efficacious against both T- and B-cell ALL, while displaying reduced acute toxicity features. These results support the development of a new generation of safer l-asparaginases without l-glutaminase activity for the treatment of human ALL.Significance: A new l-asparaginase-based therapy is less toxic compared with FDA-approved high l-glutaminase enzymes Cancer Res; 78(6); 1549-60. ©2018 AACR.

PROVIDER: S-EPMC5856643 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC5016162 | BioStudies
2016-01-01 | S-EPMC4776285 | BioStudies
2008-01-01 | S-EPMC2494961 | BioStudies
2019-01-01 | S-EPMC6428875 | BioStudies
2019-01-01 | S-EPMC6363723 | BioStudies
2020-01-01 | S-EPMC7158977 | BioStudies
2020-01-01 | S-EPMC7497903 | BioStudies
2019-01-01 | S-EPMC6597663 | BioStudies
2017-01-01 | S-EPMC5282591 | BioStudies
2019-01-01 | S-EPMC6726508 | BioStudies